SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)
AD Proal, MB VanElzakker, S Aleman, K Bach… - Nature …, 2023 - nature.com
Millions of people are suffering from Long COVID or post-acute sequelae of COVID-19
(PASC). Several biological factors have emerged as potential drivers of PASC pathology …
(PASC). Several biological factors have emerged as potential drivers of PASC pathology …
Ebola virus disease
ST Jacob, I Crozier, WA Fischer, A Hewlett… - Nature reviews Disease …, 2020 - nature.com
Ebola virus disease (EVD) is a severe and frequently lethal disease caused by Ebola virus
(EBOV). EVD outbreaks typically start from a single case of probable zoonotic transmission …
(EBOV). EVD outbreaks typically start from a single case of probable zoonotic transmission …
Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks
AK Keita, FR Koundouno, M Faye, A Düx, J Hinzmann… - Nature, 2021 - nature.com
Seven years after the declaration of the first epidemic of Ebola virus disease in Guinea, the
country faced a new outbreak—between 14 February and 19 June 2021—near the …
country faced a new outbreak—between 14 February and 19 June 2021—near the …
Ebola virus disease
D Malvy, AK McElroy, H de Clerck, S Günther… - The Lancet, 2019 - thelancet.com
Ebolaviruses are pathogenic agents associated with a severe, potentially fatal, systemic
disease in man and great apes. Four species of ebolaviruses have been identified in west or …
disease in man and great apes. Four species of ebolaviruses have been identified in west or …
Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors
J Liu, JC Trefry, AM Babka, CW Schellhase… - Science translational …, 2022 - science.org
Effective therapeutics have been developed against acute Ebola virus disease (EVD) in both
humans and experimentally infected nonhuman primates. However, the risk of viral …
humans and experimentally infected nonhuman primates. However, the risk of viral …
Joint external evaluation of the International Health Regulation (2005) capacities: current status and lessons learnt in the WHO African region
A Talisuna, AA Yahaya, SC Rajatonirina, M Stephen… - BMJ global …, 2019 - gh.bmj.com
The International Health Regulations (IHR, 2005) are an essential vehicle for addressing
global health security. Here, we report the IHR capacities in the WHO African from …
global health security. Here, we report the IHR capacities in the WHO African from …
Ebola virus antibody decay–stimulation in a high proportion of survivors
C Adaken, JT Scott, R Sharma, R Gopal, S Dicks… - Nature, 2021 - nature.com
Neutralizing antibody function provides a foundation for the efficacy of vaccines and
therapies,–. Here, using a robust in vitro Ebola virus (EBOV) pseudo-particle infection assay …
therapies,–. Here, using a robust in vitro Ebola virus (EBOV) pseudo-particle infection assay …
Recent successes in therapeutics for Ebola virus disease: no time for complacency
PL Iversen, CD Kane, X Zeng, RG Panchal… - The Lancet Infectious …, 2020 - thelancet.com
The PALM trial in the Democratic Republic of the Congo identified a statistically significant
survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute …
survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute …
Viral genomics in Ebola virus research
N Di Paola, M Sanchez-Lockhart, X Zeng… - Nature Reviews …, 2020 - nature.com
Filoviruses such as Ebola virus continue to pose a substantial health risk to humans.
Advances in the sequencing and functional characterization of both pathogen and host …
Advances in the sequencing and functional characterization of both pathogen and host …